A5016138699- Influenza Virus Research Studies
- Vaccine Coverage and Hesitancy
- Respiratory viral infections research
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Pneumonia and Respiratory Infections
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Bacterial Infections and Vaccines
- Diabetes and associated disorders
- Genomics and Rare Diseases
- Healthcare Systems and Practices
- Antifungal resistance and susceptibility
- Data-Driven Disease Surveillance
- Health Systems, Economic Evaluations, Quality of Life
- Educational Innovations and Technology
- Politics and Society in Latin America
- Global Maternal and Child Health
- Chronic Disease Management Strategies
- COVID-19 diagnosis using AI
- Literacy and Educational Practices
- COVID-19 epidemiological studies
- Child Nutrition and Water Access
- BRCA gene mutations in cancer
- Viral Infections and Outbreaks Research
- Indigenous Cultures and History
National Institute of Health Dr. Ricardo Jorge
2016-2025
Ricardo (United Kingdom)
2017-2024
Instituto Nacional de Saúde
2017-2024
George Washington University
2024
Semmelweis University
2024
Universidad del Valle
2024
Xunta de Galicia
2022
Instituto de Cardiología y Cirugía Cardiovascular
2020
Consejo Nacional de Investigaciones Científicas y Técnicas
2018
National University of the Littoral
2018
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 vaccine effectiveness (IVE) estimates two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against than A(H3N2): EU-PC 53% (95% CI: 41 63) 30% −3 54) A(H3N2). For EU-H, these were 44% 30 55) 14% −32 43), respectively.
Abstract Background Influenza A(H3N2) viruses dominated early in the 2022–2023 influenza season Europe, followed by higher circulation of A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated vaccine effectiveness (VE) using a multicentre test‐negative study. Materials Methods Primary practitioners collected information specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, (sub)type clade, age group, target group time since...
We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 season Europe. Among 5547 SARI ≥18 years, 2963 (53%) were vaccinated influenza. Overall VE A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% -4-39) A(H3N2) and 56% 22-75) B. During season, while hospitalisation B >55%, it ≤20% for A subtypes. While vaccination should be...
We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory from five countries Europe. Bivalent provided short-term additional protection compared those vaccinated > 6 months before campaign: 80% (95% CI: 50 94) for 14–89 days post-vaccination, 15% −12 35)...
Introduction Influenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences vaccine effectiveness (VE). Aim The I-MOVE multicentre primary care test-negative study assessed 2018/19 VE age genetic subgroups to explore cohort. Methods We measured against (sub)clades. stratified usual groups (0–14, 15–64, ≥ 65-years). To assess the imprint-regulated effect of (I-REV) hypothesis,...
Introduction In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods Individuals with or acute respiratory symptoms at primary care/community level 10 European countries were tested for SARS-CoV-2. We complete course overall VE by brand time since vaccination. Results Overall was 74% (95% CI: 69–79), 76% 71–80), 63% 48–75) 16–83) among those...
Background. Severe acute respiratory infections (SARI) surveillance is recommended to assess the severity of disease. In 2021, National Institute Health Doutor Ricardo Jorge, in collaboration with two general hospitals, implemented a SARI sentinel system based on electronic health registries. We describe its application 2021/2022 season and compare evolution cases COVID-19 influenza activity regions Portugal. Methods. The main outcome interest was weekly incidence patients hospitalized due...
We estimated the effectiveness of adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine was 46% at 14-59 days and 34% 60-119 days, no effect thereafter. The conferred protection BA.2.86 lineage first 4 months post-vaccination.
<h3>Background</h3> <i>Curanderismo</i>("the healing") is a centuries-old synthesis of Mexican Indian culture and beliefs. <h3>Objective</h3> To evaluate the rate use of<i>curanderismo</i>among Hispanic subjects seeking medical care at Denver Health Medical Center, Denver, Colo. <h3>Methods</h3> We conducted survey 405 attending outpatient primary urgent clinics public hospital system for Denver. The main outcome measure was independent predictors of<i>curanderos</i>. <h3>Results</h3> Of...
We conducted a multicentre test-negative case-control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential...
ABSTRACT We conducted a multicentre test‐negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. provide early estimates of effectiveness newly adapted XBB.1.5 COVID‐19 vaccines against PCR‐confirmed SARS‐CoV‐2 hospitalisation. Vaccine was 49% overall, ranging between 69% at 14–29 days and 40% 60–105 post vaccination. The conferred protection hospitalisation first...
In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% CI: 2 43) among 65-79-year-olds and 13% -15 30) those ≥ 80 years. As the component has not changed for 2017/18, physicians public health experts should be aware that could low where viruses predominate.
Integrated approaches to surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection are important for public health actions. The 2nd National Serological Survey (ISN2COVID-19) aimed characterize the extent SARS-CoV-2 and vaccine-induced response in Portuguese population following third epidemic wave launch vaccination campaign.A cross-sectional study was performed using data on 8463 1-79 years age, collected February March, 2021. IgM IgG (anti-nucleoprotein...
In critically ill children, Candida species and other yeasts appear as an important nosocomial pathogen. The emerging fungal pathogens are usually less susceptible to azole compounds, the management of such infections could be problematic.6,065 bloodstream cultures 627 catheters from intensive care units hospitalized oncology pediatric patients were studied. Antifungal susceptibility testing isolates was performed according reference broth microdilution method describedby National Committee...
Within influenza vaccine effectiveness (VE) studies at primary care level with a laboratory-confirmed outcome, clinical case definitions for recruitment of patients can vary. We used the 2022-23 VEBIS European multicentre study end-of-season data to evaluate whether definition affected IVE estimates.
Importance In the context of emerging SARS-CoV-2 variants or lineages and new vaccines, it is key to accurately monitor COVID-19 vaccine effectiveness (CVE) inform vaccination campaigns. Objective To estimate vaccines administered in autumn winter 2022 2023 against symptomatic infection (with all circulating viruses XBB lineage particular) among people aged 60 years older Europe, compare different CVE approaches across exposed reference groups used. Design, Setting, Participants This...
Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe 2017-18, predominated by influenza B. WHO-recommended, trivalent vaccine components were lineage-mismatched for The I-MOVE hospital network measured 2017-18 seasonal effectiveness (IVE) against A(H3N2) among hospitalised patients (≥65 years) Europe. Following the same generic protocol test-negative design, teams nine countries swabbed ≥65 years with recent onset (≤7 days) severe acute respiratory infection (SARI),...
The aim of this study was to estimate the excess mortality associated with influenza activity registered in Portugal between week 49 2008 and 5 2009. For purpose available data from Portuguese Daily Mortality Monitoring (VDM) System were used. Several estimates deaths recent recorded determined through statistical modelling (cyclic regression) for total population disaggregated by gender age group. results show that impact 2008-9 season 1,961 deaths, approximately 82% these occurring group...
Background Pneumonia is one of the leading causes mortality and has a high burden in morbidity. In Portugal, 7-valent pneumococcal conjugated vaccine (PCV) was used since 2001 PCV10/13 2009, being last introduced into National Immunization Program 2015. Methods We conducted an ecological study to evaluate impact PCV7 PCV13 on pneumonia (PP) hospitalizations adults aged 65 years or more Portugal. hospital discharge registry data from 1998/99 2015/16 were used, PP hospitalization defined as...
The aim of this study was to determine the distribution and antifungal susceptibility profile yeast species isolated from neonates in Neonatal Intensive Care Units (NICU) northeast Argentina. With purpose 92 strains 25 blood stream cultures, 20 venous catheters, 23 suprapubic aspirations 24 rectal swabs were studied. Candida albicans C. parapsilosis appeared with similar frequencies (36%) isolates. (50%) most frequent catheters colonizer tropicalis (54.2%) associated gastrointestinal tract...
Current data on antimicrobial resistance in pig production is essential for the follow-up strategic programs to eventually preserve effectiveness of last-resort antibiotics humans. Here, we characterized 106 Escherichia coli recovered routine diagnosis (2020-2022) from fecal sample pigs, belonging 74 Spanish industrial farms, affected by diarrhea. The analysis virulence-gene targets associated with pathotypes E. coli, determined 64 as pathogenic and 42 commensal. Antimicrobial susceptibility...
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥18 years hospitalised with severe acute respiratory infection in Europe. provide early estimates of effectiveness newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine was 48% overall, ranging between 68% at 14–29 days and 40% 60–105 post vaccination. The conferred protection hospitalisation first 3.5 months...
ABSTRACT We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS‐CoV‐2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage‐predominant period in a European multi‐country test‐negative case–control study at primary care level. VE adjusted by site, age, sex, chronic conditions and onset date. included 220 cases 1733 controls. The was 48% (95% CI: 12–71), 23% −11–48) 5% −92–56) those with symptom 1–5, 6–11, 12 weeks after vaccination, respectively. provided...